Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report)’s share price rose 4.6% during trading on Tuesday after Barclays raised their price target on the stock from $44.00 to $45.00. Barclays currently has an overweight rating on the stock. Scholar Rock traded as high as $38.31 and last traded at $38.1370. Approximately 163,491 shares traded hands during trading, a decline of 90% from the average daily volume of 1,629,198 shares. The stock had previously closed at $36.47.
A number of other research analysts have also recently commented on SRRK. Jefferies Financial Group assumed coverage on shares of Scholar Rock in a research report on Thursday, August 21st. They set a “buy” rating and a $50.00 price target on the stock. Leerink Partnrs raised shares of Scholar Rock to a “strong-buy” rating in a research note on Monday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research report on Wednesday, October 8th. BMO Capital Markets reissued an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a research note on Friday. Finally, Leerink Partners assumed coverage on shares of Scholar Rock in a research report on Monday, September 15th. They set an “outperform” rating and a $51.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $48.45.
View Our Latest Stock Report on Scholar Rock
Insiders Place Their Bets
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Lord Abbett & CO. LLC increased its holdings in shares of Scholar Rock by 86.2% in the 1st quarter. Lord Abbett & CO. LLC now owns 877,374 shares of the company’s stock worth $28,207,000 after purchasing an additional 406,074 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Scholar Rock by 2.5% during the first quarter. Northern Trust Corp now owns 765,280 shares of the company’s stock valued at $24,604,000 after purchasing an additional 18,753 shares in the last quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. boosted its position in shares of Scholar Rock by 145.3% during the second quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 769,442 shares of the company’s stock valued at $27,254,000 after buying an additional 455,753 shares during the last quarter. Intech Investment Management LLC increased its holdings in Scholar Rock by 60.9% in the 1st quarter. Intech Investment Management LLC now owns 56,784 shares of the company’s stock worth $1,826,000 after buying an additional 21,483 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Scholar Rock in the 1st quarter worth about $458,000. Institutional investors own 91.08% of the company’s stock.
Scholar Rock Stock Up 4.5%
The company’s 50 day simple moving average is $32.55 and its 200-day simple moving average is $33.43. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 0.21. The firm has a market cap of $3.66 billion, a P/E ratio of -13.10 and a beta of 0.79.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the previous year, the firm earned ($0.66) EPS. Research analysts forecast that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
See Also
- Five stocks we like better than Scholar Rock
- What Investors Need to Know to Beat the Market
- 3 Smart Defensive Stocks for an Uneasy Market
- Canada Bond Market Holiday: How to Invest and Trade
- These 3 Stocks Are Using Buybacks to Signal Market Confidence
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Companies to Watch as Natural Gas Stocks Make a Comeback
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.
